Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 11, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Editor's Note: The "Qiming Weekly" column is published regularly every week, rounding up funding news and development updates from Qiming Venture Partners' portfolio companies.
In the wave of technology and innovation, every step entrepreneurs take is worth documenting. Qiming Venture Partners will continue to accelerate and empower entrepreneurs, and we invite you to join us in marking the milestone moments of our portfolio companies.
Funding News
01/
Tashi Zhihang Raises $120 Million in Angel Round Qiming Venture Partners Co-Leads
Recently, embodied AI startup Tashi Zhihang (TARS) announced the completion of a $120 million angel round, embarking on a new journey in embodied AI entrepreneurship. This round was co-led by Qiming Venture Partners. Tashi Zhihang set a record for the largest angel-round funding in China's embodied AI industry. The proceeds will primarily be used for product and technology R&D, model training, and scenario expansion.
Founded on February 5, 2025, Tashi Zhihang is uniquely positioned in the industry as a company simultaneously possessing embodied AI large model capabilities, hardware R&D capabilities, and mass production capacity for integrated software-hardware products. On the technical front, Tashi Zhihang has established a new paradigm for embodied AI development, pioneering the industry's Human-Centric Embodied Data Engine, which enables a leapfrog breakthrough in real-world embodied data acquisition capabilities — injecting strong momentum into the sustained development of physical-world AI. At the same time, Tashi Zhihang has also pioneered the industry's first spatial perception and reasoning decision-making integrated embodied large model, accelerating the GPT moment for embodied AI technology through the creation of a data-driven, generalizable universal physical-world intelligent system.
Alex Zhou, Managing Partner at Qiming Venture Partners, stated, "Qiming Venture Partners began systematically deploying in artificial intelligence, robotics, and autonomous driving ten years ago. We have accompanied companies in these fields through their growth, witnessing firsthand from the industry's frontier the gradual fusion of AI technology with the physical world, and the continuous breakthroughs in algorithms and hardware. China boasts strong R&D capabilities in AI, a wealth of talent, and the world's most complete hardware ecosystem, rich landing scenarios, and vast market potential — making it highly likely to cultivate embodied AI and robotics companies with global competitiveness and industry-leading capabilities. Venturing into this field requires not only deep insight into frontier technology trends, but also extensive experience in engineering, productization, and mass production. We believe Tashi Zhihang is one of the few excellent teams in the industry with complete capabilities."
02/
Yuanling Lingji Raises 200 Million Yuan in Angel Round Qiming Venture Partners Invests
Embodied AI startup Yuanling Lingji (Chongqing) Intelligent Technology Co., Ltd. ("Yuanling Lingji") announced the completion of a 200 million yuan angel round, with investors including Qiming Venture Partners.
Yuanling Lingji's R&D team combines top-tier academic backgrounds with over ten years of experience in AI-native product commercialization, making it one of the few embodied AI companies in the industry with both large model technology and robotics scenarios.
Major Partnerships
01/
Dongfeng Liuzhou Motor to Deploy Multiple UBTECH Industrial Humanoid Robots Marks World's First Batch Deployment of Humanoid Robots in Auto Factory
Recently, Dongfeng Liuzhou Motor announced it will deploy 20 industrial humanoid robots Walker S1 from Qiming Venture Partners portfolio company UBTECH (09880.HK) in its automotive manufacturing plant, with plans to complete the deployment in the first half of the year for vehicle manufacturing — enhancing the plant's intelligence, unmanned operation levels, and efficiency. This marks the world's first batch deployment of humanoid robots in an automotive factory.
Following pilot testing, Dongfeng Liuzhou Motor will deploy the Walker S1 industrial humanoid robots to perform seatbelt inspection, door lock inspection, headlight cover inspection, trunk inspection, interior final inspection, fluid filling, front axle sub-assembly, kit picking, emblem application, configuration flashing, label printing, and material handling — actively advancing the application of AI technology in automotive manufacturing.
02/
Hesai Technology Secures Mass Production Designation from Chery Automobile's EV Brand iCAR
Recently, Qiming Venture Partners portfolio company Hesai Technology (NASDAQ: HSAI) announced it has secured a mass production designation from iCAR, Chery Automobile's new energy vehicle brand. In this partnership, Hesai Technology will enable iCAR's new model to implement high-level intelligent driving with lidar, with the first collaborative model planned for mass production in Q4 2025 — equipped with Hesai Technology's compact ultra-high-definition long-range lidar ATX.
The addition of Hesai Technology's lidar will bring more high-definition, comprehensive 3D perception capabilities to iCAR, enhancing the vehicle's environmental awareness in complex scenarios such as automatic emergency braking, adaptive cruise control, urban NOA, and intelligent parking. It will also help vehicles identify potential hazards earlier and respond accordingly, becoming an indispensable "functional component" and "safety component" in high-level intelligent driving.
03/
Hesai Technology AT128 Powers JiuZhi's Autonomous Vehicles Past 10 Million Kilometers in L4 Operations
Recently, JiuZhi announced that its third-generation mass-produced urban delivery autonomous vehicles have surpassed 100 days since delivery, with L4 operational mileage exceeding 10 million kilometers. The series features a "flat-top" design, equipped with 4 AT128 lidar units from Qiming Venture Partners portfolio company Hesai Technology (NASDAQ: HSAI) combined with 13 cameras — delivering not only a cleaner, more aesthetic vehicle appearance but also greater flexibility.
Hesai Technology's AT128 features automotive-grade reliability, enabling JiuZhi's autonomous vehicles to achieve 24/7 efficient operation in all conditions. Its core components use automotive-grade devices meeting AEC-Q and other international standards, passing over 50 automotive-grade tests covering electrical, mechanical, climatic, sealing, material, and electromagnetic compatibility aspects. This high-reliability design ensures stable operation in complex environments, providing precise long-range perception for autonomous vehicles. Even under complex weather conditions, the autonomous delivery vehicles maintain stable operation, ensuring safe and efficient package delivery.
04/
Yunji Technology and Qihoo 360 Enterprise Security Group Form Strategic Partnership Jointly Building Security Defenses for Robot Service Agents
Recently, Qiming Venture Partners portfolio company Yunji Technology announced a strategic partnership with Qihoo 360 Enterprise Security Group, a leader in cybersecurity.
The two sides will carry out in-depth product and technology cooperation around building secure robot service agents, aiming to strengthen comprehensive security protection upgrades for robot service agents through technological innovation and joint development of industry security standards, advance the implementation of "robot security ID cards," and promote the healthy development of China's service agent industry.
05/
Yingying Medical Becomes Shanghai's First Private Medical Institution to Offer Mayo Clinic eConsult Services
Recently, Qiming Venture Partners portfolio company Yingying Medical officially launched its eConsult (electronic consultation) partnership with Mayo Clinic, providing patients with authoritative, professional second opinions. This collaboration marks an important step for Yingying Medical in integrating international medical resources and delivering high-quality diagnostic and treatment services, while also making it the first private medical institution in Shanghai to offer Mayo Clinic eConsult services.
eConsult is a remote medical consultation service. Through a remote platform, Yingying Medical physicians invite Mayo Clinic specialists to participate in consultations. After reviewing the patient's complete medical records, the specialists provide professional written opinions. Yingying Medical ensures efficient and compliant international consultation processes, with full coverage of complex areas including oncology, rare diseases, and cardiovascular conditions.
06/
CanSino Biologics Signs Vaccine Cooperation Agreement with Saudi SPIMACO
Recently, Qiming Venture Partners portfolio company CanSino Biologics (688185.SH, 06185.HK) formally signed a vaccine cooperation agreement with Saudi Arabian pharmaceutical manufacturer SPIMACO. The two parties will collaborate to accelerate the entry of Menhycia®, a quadrivalent meningococcal conjugate vaccine, into Saudi Arabia and other Middle Eastern and North African markets, while also promoting joint R&D and local production system development.
Dr. Xuefeng Yu, Chairman and CEO of CanSino Biologics, emphasized that the partnership with SPIMACO represents an important milestone in the company's expansion into the Middle East and North Africa markets. CanSino Biologics remains committed to providing innovative, high-quality, and accessible vaccines to address unmet medical needs in the region.
07/
Insilico Medicine Announces Strategic Partnership with Mabwell Biotech
Recently, Qiming Venture Partners portfolio company Insilico Medicine entered into a strategic partnership with Mabwell Biotech. The collaboration will leverage each party's respective technological strengths in ADC R&D and artificial intelligence to empower ADC innovative drug development with AI.
Under the cooperation agreement, the two parties will combine their platform advantages to develop next-generation payload toxins with novel biological mechanisms, innovative structures, and pharmaceutical activity, enhancing ADC innovation efficiency and supporting upgrades to the AI platform.
08/
Asieris Pharma and Xiling Pharmaceutical Sign Strategic Cooperation Memorandum for Gynecologic Oncology Products
Recently, Qiming Venture Partners portfolio company Asieris Pharma (688176.SH) announced the formal signing of a "Strategic Cooperation Memorandum for Gynecologic Oncology Products" with Xiling Pharmaceutical. The partnership will be based on eribulin mesylate injection (hereinafter referred to as "eribulin"), a novel tubulin inhibitor for treating advanced breast cancer, while also exploring opportunities for collaboration on other gynecologic oncology products to achieve mutual benefit and win-win outcomes.
Ying Xu, Chief Commercial Officer of Asieris Pharma, stated: "Xiling Pharmaceutical has deep expertise in the gynecologic oncology field. This strategic partnership will fully leverage our respective strengths to accelerate the commercialization of eribulin. Combined with Asieris Pharma's presence in breast cancer and gynecologic oncology, this will further strengthen the company's commercial capabilities, improving product accessibility and affordability, and bringing more hope for cure and survival to patients."
09/
Yuanxin Huibao and Grand Pharmaceutical Reach Strategic Partnership to Jointly Advance Pharmaceutical Payment Innovation
Recently, Qiming Venture Partners portfolio company Yuanxin Huibao formally signed an innovative access strategic cooperation agreement with Grand Pharmaceutical. With "inclusive healthcare and patient accessibility" as the core objective, the two parties will cooperate in inclusive insurance, commercial health insurance, innovative payment, instant retail, and health management services, achieving resource sharing and complementary advantages. The aim is to improve patient access to innovative and high-quality drugs and medical devices by jointly driving the deep development of commercial insurance products.
According to the agreement, both parties plan to implement cooperation projects within 2025, covering major disease areas including oncology, rare diseases, and chronic diseases. Together they will build an ecosystem of "accessible payment, sustainable medication, and manageable health." Through innovative breakthroughs in commercial insurance payment, more patients will be able to access and afford Grand Pharmaceutical's anti-tumor drugs, precision interventional products for cardiovascular and cerebrovascular conditions, and globally leading diagnostic agents.
R&D Progress
01/
Zai Lab to Present Data on Next-Generation Antitumor Drug Candidates at AACR Annual Meeting
Recently, Qiming Venture Partners portfolio company Zai Lab (NASDAQ: ZLAB, 09688.HK) announced that it will present preclinical research data on its internally developed next-generation antitumor therapies ZL-6201 (an LRRC15 ADC for treating sarcoma) and ZL-1222 (an IL-12 immunocytokine cancer immunotherapy) during the poster sessions at the 2025 American Association for Cancer Research (AACR) Annual Meeting.
Dr. Rafael G. Amado, President and Global Head of R&D at Zai Lab, stated: "ZL-6201 and ZL-1222 are investigational candidates from our internally developed global oncology pipeline, with potential applications across multiple cancer types, including some where standard of care remains challenging. This aligns with our global oncology pipeline development strategy."
02/
MediLink Therapeutics Presents Updated Efficacy Data for YL201 at 2025 European Lung Cancer Conference
Recently, Qiming Venture Partners portfolio company MediLink Therapeutics announced updated intracranial efficacy data for YL201 in lung cancer patients at the 2025 European Lung Cancer Congress (ELCC) annual meeting. YL201 is a B7H3-targeting antibody-drug conjugate (ADC) developed on MediLink's TMALIN® platform.
Dr. Xuke Qin, Chief Medical Officer of MediLink Therapeutics, stated: "At ESMO 2024, MediLink Therapeutics presented Phase 1 efficacy and safety data for YL201 across multiple solid tumors, including lung cancer. The data presented at this ELCC congress provides powerful supplementary evidence, further demonstrating YL201's therapeutic effect in lung cancer patients, particularly those with brain metastases. Given that brain metastases significantly impact prognosis in lung cancer patients, our current results represent a very encouraging signal. YL201 has already advanced to Phase 3 clinical studies in small cell lung cancer, and we believe the data presented at this congress will further strengthen our confidence in YL201's ability to treat these patients."
03/
Belief BioMed's BBM-A101 Gene Therapy
Knee Osteoarthritis Clinical Trial Application Approved in China
Recently, Qiming Venture Partners portfolio company Belief BioMed announced that the clinical trial application (IND) for its knee osteoarthritis (KOA) gene therapy drug BBM-A101 injection has been approved by the National Medical Products Administration (NMPA).
Dr. Xiao Xiao, co-founder, chairman, and chief scientist of Belief BioMed, stated: "China's aging population is accelerating, and the burden of chronic diseases continues to grow. Building on our extensive experience in developing and manufacturing gene therapies for rare diseases, Belief BioMed is actively expanding into gene therapies for chronic conditions. BBM-A101 injection utilizes an AAV vector to deliver a human anti-inflammatory protein gene to the patient's knee joint for sustained expression, potentially achieving 'one dose, long-term efficacy' treatment for knee osteoarthritis. This approval marks another important milestone for Belief BioMed. Moving forward, we will accelerate clinical study progress with the goal of bringing a new treatment option to patients as soon as possible."
04/
Oricell Therapeutics Presents Preclinical Data on Innovative GPRC5D and BCMA Bispecific CAR-T Therapy
Recently, Qiming Venture Partners portfolio company Oricell Therapeutics announced that preclinical study data for its independently developed innovative GPRC5D and BCMA bispecific CAR-T therapy (BCMAxGPRC5D Bi-specific CAR-T) will be presented at the 2025 American Association for Cancer Research (AACR) annual meeting.
Study results indicate that this product, which simultaneously targets both BCMA and GPRC5D, demonstrates breakthrough potential in treating high-risk, relapsed/refractory (R/R), heterogeneous multiple myeloma (MM), and can overcome key therapeutic obstacles including antigen escape, tumor microenvironment (TME) tolerance, and antigen expression heterogeneity.
05/
LokiBio Announces Completion of LQ036 Phase 2a Clinical Study
Recently, Qiming Venture Partners portfolio company LokiBio announced that its core inhaled product LQ036 (an IL-4Rα-targeting single-domain antibody) successfully completed a Phase 2a proof-of-concept (POC) clinical study in patients with moderate-to-severe asthma. Study results showed that LQ036 demonstrated rapid, significant, and sustained anti-inflammatory pharmacological effects, with good safety and tolerability — an encouraging outcome that lays a solid foundation for the upcoming Phase 2b clinical trial and further development.
Dr. Yakun Wan, founder, chairman, and CEO of LokiBio, stated: "As the world's first inhaled nanobody drug targeting IL-4Rα, LQ036 has the potential to break through the limitations of existing biologic treatments for respiratory diseases and fill a gap in this field. The success of this Phase 2a proof-of-concept study further validates LQ036's substantial clinical efficacy potential and consistent safety profile, strengthening our confidence in rapidly advancing to Phase 2b clinical studies. We look forward to LQ036 continuing to achieve breakthroughs in upcoming clinical trials and bringing better treatment options to asthma patients worldwide as soon as possible."
06/
AusperBio Clinical Research Selected for Late-Breaking Oral Presentation at APASL Annual Meeting
Recently, Qiming Venture Partners portfolio company AusperBio announced that Phase 2a clinical study results for its innovative antisense oligonucleotide drug AHB-137 have been selected for the Late-Breaking Abstracts session at the 34th Asian Pacific Association for the Study of the Liver (APASL) annual meeting, with data presented as an oral report.
The study showed that HBeAg-negative chronic hepatitis B patients receiving nucleos(t)ide analogue (NA) therapy achieved significant HBsAg clearance after 24 weeks of AHB-137 treatment, with sustained response 8 weeks after discontinuation. Guided by its core philosophy of "patient needs driving R&D," AusperBio is actively advancing the global shift in liver disease treatment from "long-term control" to "clinical cure," fully supporting the WHO's goal of eliminating hepatitis by 2030.
07/
Asieris Subsidiary Baylink to Present Two Research Studies at 2025 AACR Annual Meeting
Recently, Qiming Venture Partners portfolio company Asieris Pharmaceuticals (688176.SH) announced that its subsidiary Baylink will present two latest research studies in poster format at the 2025 American Association for Cancer Research (AACR) annual meeting.
The two poster presentations include "Antibody-Drug Conjugate (ADC) Linker Platform: Broadening the Therapeutic Window" and "Preclinical Evaluation of BLB-101: A CLDN6/9-Targeting Antibody-Drug Conjugate (ADC) with Proprietary Hydrophilic Linker and Topoisomerase Inhibitor Payload."
Product Launches
01/
Renodx's Ultra-High-Throughput SuperSAT
Fully Automated Isothermal Nucleic Acid Amplification Analysis System Approved for Market
Recently, Qiming Venture Partners portfolio company Renodx (688193.SH) received approval from the National Medical Products Administration for its SuperSAT fully automated isothermal nucleic acid amplification analysis system (registration number: Guo Xie Zhu Zhun 20253220955). This innovative instrument, combining ultra-high throughput, ultra-compact footprint, and maximum flexibility, injects new momentum into the field of pathogen RNA diagnostics.
SuperSAT is currently one of the very few ultra-high-throughput fully automated nucleic acid testing systems in China. It is compatible with all SAT assay reagent series, supports simultaneous detection of up to five targets via multi-channel fluorescence, and features a triple contamination-prevention design to safeguard laboratory safety.
02/
Shukun Technology's 4 AI Products Receive
EU Medical Device Regulation Certification
Recently, four AI products independently developed by Qiming Venture Partners portfolio company Shukun Technology — ischemic stroke CT image-assisted assessment software, intracranial hemorrhage CT image-assisted triage software, coronary artery calcium scoring-assisted assessment software, and rib fracture CT image-assisted detection software — have successfully obtained certification under the European Union Medical Device Regulation (MDR).
With this, Shukun Technology has accumulated a total of 10 EU MDR certifications, covering the three critical areas of heart, brain, and chest, as well as full-disease-cycle management for coronary heart disease, stroke, and lung cancer. Its AI technical capabilities have reached world-class levels, injecting new momentum into the intelligent upgrading of the global healthcare industry.
Technology Strength
01/
WeRide Obtains French Driverless License
Becomes Only Autonomous Driving Tech Company with Licenses in Five Countries
Recently, Qiming Venture Partners portfolio company and global leading autonomous driving technology firm WeRide (NASDAQ: WRD) announced its partnership with French autonomous mobility network operator beti to obtain a French pure driverless public road testing and operating license (hereinafter referred to as "the license").
WeRide has thus become the world's first and, to date, only technology company to hold autonomous driving licenses in five countries — China, the UAE, Singapore, France, and the United States — fully demonstrating its strong cross-border market applicability in technology and its mature compliance, safety, and reliability in operations.
From application to final approval, WeRide and beti took only three months, setting a record for autonomous driving companies obtaining licenses in France. This also means WeRide has met the highest European standards in technical safety verification and operational program design. The license permits WeRide's autonomous minibuses to operate at 40 km/h, the highest speed currently approved in France for pure driverless road testing and operation.
02/
Zhipu AI Releases AutoGLM Zhensi, First Intelligent Agent with Deep Research and Operational Capabilities
Recently, Qiming Venture Partners portfolio company Zhipu AI officially launched AutoGLM Zhensi at the Zhongguancun Forum. This new intelligent agent not only possesses deep research capabilities (Deep Research) but can also perform actual operations (Operator), truly advancing intelligent agents into a stage of "thinking while doing."
The AutoGLM Zhensi model released this time is the world's first intelligent agent integrating both deep research and operational capabilities. This represents an important advancement in autonomous agent technology and a further upgrade of device-control intelligent agents.
Zhipu AI has always focused on foundational AGI model research and development, and has currently progressed to the L3-Agentic LLM stage. Regarding industry ecosystem development, Zhipu AI insists on co-creation with industry partners, leveraging its accumulated expertise in large model R&D to help partners succeed and jointly build successful large model applications. Zhipu AI is also actively promoting the overseas expansion of China's original large models and solutions.
03/
Shengshu Technology Releases Multimodal Highly Controllable Video Generation Model
At the AI Day keynote of the Zhongguancun Forum, Jun Zhu, Vice Dean of Tsinghua University's Institute for Artificial Intelligence and Founder and Chief Scientist of Qiming Venture Partners portfolio company Shengshu Technology, released the multimodal video generation model Vidu Q1. This model focuses on "high controllability," aiming to address the "randomness" pain point in current AI video generation. The model launched globally in April.
Vidu Q1 achieves significant breakthroughs in multi-subject detail control (particularly motion and layout control), audio-visual synchronization control, and image quality enhancement. Additionally, Vidu Q1 can further enhance image quality, delivering clearer, more refined, and more realistic visual experiences to users.
04/
CanSino Biologics Appears at VIF World 2025
Building a Healthier Future Through Technical Innovation and Global Collaboration
At the 6th Vaccine Innovation Forum World 2025 (VIF World 2025), Qiming Venture Partners portfolio company CanSino Biologics (688185.SH, 06185.HK) appeared as a representative of China's innovative vaccine enterprises, focusing on core topics such as vaccine R&D, production, and globalization. The company engaged in in-depth discussions with attendees on frontier technologies, success stories, and practical experiences, jointly promoting innovation, cooperation, and sustainable development in the global vaccine industry.
CanSino Biologics shared its practices in localized manufacturing, science education, and demand-oriented innovative development, providing multi-dimensional solutions for global vaccine equity. The company also showcased its breakthrough progress in tuberculosis vaccines, highlighting the profound impact of China's biopharmaceutical industry on global public health.
05/
Rendu Biotechnology Debuts New Product at the 22nd CACLP
At the 22nd China Association of Clinical Laboratory Practice (CACLP) Expo, Qiming Venture Partners portfolio company Rendu Biotechnology (688193.SH) debuted its newly launched product — the SuperSAT fully automated isothermal nucleic acid amplification analysis system — injecting fresh vitality into the molecular diagnostics field. With its ultra-high throughput, ultra-compact footprint, and maximum flexibility, the product became a focal point of industry attention.
The SuperSAT fully automated isothermal nucleic acid amplification analysis system not only achieves major technical breakthroughs but also demonstrates strong adaptability and advantages in practical application. It will bring new transformation to the pathogen RNA diagnostics field, providing medical institutions with more efficient, precise, and safe testing solutions, and helping the healthcare industry reach new heights in disease diagnosis and prevention.
06/
Peru's Dos de Mayo National Hospital Adopts
VINNO's Latest Portable Ultrasound VINNO 10
Following the large-scale deployment of 173 high-end color ultrasound systems from Qiming Venture Partners portfolio company VINNO in Peru's La Libertad region in 2024 to improve basic medical care, Dos de Mayo National Hospital recently announced the adoption of VINNO's latest portable ultrasound VINNO 10, dedicated to elevating the standard of liver surgery.
During preoperative planning and surgery, it's critical for doctors to directly assess liver organ status and adjust the approach in real time. Dr. Edwin Damián Bello, a specialist in the First Surgery Department at Peru's Dos de Mayo National Hospital, emphasized: "Tiny cysts, tumors, and nodules that traditional CT scans or MRI struggle to detect can now be rapidly located and precisely addressed with the VINNO 10 — a qualitative leap in surgical efficiency and success rates."
For postoperative management, physicians can use the device to perform convenient ultrasound examinations on hospitalized patients, helping detect post-surgical complications early, monitor organ function in real time, and dynamically assess recovery progress. Dr. Edwin Damián Bello noted: "This allows us to track patients more closely and efficiently, significantly improving their recovery experience."
07/
Shenzhen HugeMed Debuts at European Association of Urology Annual Congress
At the European Association of Urology (EAU) annual congress, Qiming Venture Partners portfolio company Shenzhen HugeMed unveiled its latest products.
Among them, HugeMed's flagship new release — a disposable digital flexible ureteroscope with an outer diameter of just 4Fr — is leading minimally invasive interventional therapy into a new era with its thinner, smoother performance. In addition, the company's exhibited products, including disposable digital ureterorenoscope catheters, digital cystoureteroscopes, and disposable digital bladder imaging catheters, demonstrate its leading position and outstanding innovation capabilities in the global urology field.
08/
First Affiliated Hospital of Kunming Medical University Completes Two Surgeries Using MicroPort EP MedTech 3D Pulsed Field Ablation System
Recently, the Heart Center at the First Affiliated Hospital of Kunming Medical University successfully completed two persistent atrial fibrillation ablation procedures using Qiming Venture Partners portfolio company MicroPort EP MedTech's (688617.SH) self-developed Pulstamper™ disposable magnetic-electropositioning circular pulsed field ablation catheter and AForcePlus™ disposable magnetic-electropositioning pressure-sensing pulsed field ablation catheter.
The surgeries were performed by the cardiovascular team led by Director Wang Jing at the First Affiliated Hospital of Kunming Medical University. Wang Jing commented: "In traditional surgical treatment of persistent atrial fibrillation, linear ablation of the mitral isthmus is the biggest obstacle. Previously, Marshall vein ethanol ablation was used as an adjunct to block this region. Now, pulsed field ablation (PFA) can effectively block mitral isthmus conduction by adjusting field strength and pulse width to discharge on the endocardial surface according to the characteristics of different sites — greatly improving surgical efficiency while reducing fluoroscopy exposure and postoperative arrhythmia incidence."
09/
Pulnovo Medical Hosts 2025 PADN China-US Master Class, Building New Platform for International Expert Exchange
Recently, Qiming Venture Partners portfolio company Pulnovo Medical hosted the 2025 PADN Master Class across three Chinese cities — Nanjing, Xiamen, and Changsha — attracting cardiovascular specialists from the United States, Hong Kong, Macau, Taiwan, and other regions.
This high-level training program focused on Pulmonary Artery Denervation (PADN) centered on core themes including clinical application, surgical standards, and technical pathways. Through a combination of lectures, intraoperative observation, and case discussions, it established a new model for international exchange with Chinese experts at the core.
While providing core products and clinical solutions, Pulnovo Medical is also building an open, collaborative international academic ecosystem, working with frontline clinical experts to advance the implementation of multicenter research.
10/
Baypro's First HTProX Installed at Shenzhen Bay Laboratory
Recently, Qiming Venture Partners portfolio company Baypro announced the installation of its HTProX fully automated proteomics sample preparation workstation at Shenzhen Bay Laboratory.
The product represents the culmination of Baypro's SISPROT technology. It enables high-throughput, efficient processing — completing sample preparation for 96 cases in a single run, with capacity reaching 200 cases within 8 hours, more than 10 times faster than traditional manual operations, helping laboratories meet large-scale proteomics research demands. The system features microsample compatibility, supporting ultra-low starting sample quantities of 1μg–10μg, with SISPROT-Auto kits achieving >75% digestion efficiency and >50% peptide recovery rates, ideally suited for precious research samples. Full-process automation ensures data stability. Through environmentally intelligent design, waste volume is only 1/10 that of comparable products. The open-source software supports workflow customization to meet laboratory-specific needs.
Company Honors
Four Qiming Venture Partners Portfolio Companies Selected for 3rd PharmaCube TOP15 Annual Rankings
At the recently held 2025 PharmaCube Capital & Investment Conference and 3rd PharmaCube TOP15 Rankings Release Ceremony, rankings including China Innovative Drug Venture Capital Institutions TOP15, China Innovative Drug Emerging Enterprises TOP15, and China Innovative Drug Business Development TOP15 were unveiled. The selection aims to establish benchmark investment institutions and enterprises with annual风向标 significance for China's pharmaceutical industry.
Qiming Venture Partners portfolio company Ze'an Biopharmaceutical was selected for the China Innovative Drug Emerging Enterprises TOP15 list, while LaNova Medicines, MediLink Therapeutics, and Allorion Therapeutics were named to the China Innovative Drug Business Development TOP15 list.
Previous Issues
Qiming Weekly | Qiming Venture Partners Portfolio Company Financing and Updates Vol. 10, 2025 Qiming Honors | Qiming Venture Partners and Four Portfolio Companies Selected for 3rd PharmaCube TOP15 Annual Rankings
Qiming Stars | Qiming Venture Partners Co-Leads Tashi Zhihang's $120M Angel Round
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in the Technology and Consumer (T&C) and Healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies. More than 210 of these have gone public on exchanges including the NYSE, Nasdaq, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or have exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many of Qiming's portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, ClinChoice, Belief BioMed, Biren Technology, and others.